DuPont Merck, Barr NOV letters mark ad division effort to referee generic substitution dispute.
DUPONT MERCK DISCUSSION OF AVERAGE BIOEQUIVALENCE "SHORTCOMINGS" ARE APPROPRIATE, the company maintained after receiving an Aug. 26 notice of violation letter from FDA's Division of Drug Marketing, Advertising & Communications. The letter charged that DuPont Merck "made misleading statements about bioequivalence" of generic warfarin in Coumadin slide presentations, DDMAC Deputy Director Norman Drezin reported at a Food & Drug Law Institute meeting Sept. 3 in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth